Trust Co. of Oklahoma raised its holdings in Merck & Co., Inc. (NYSE:MRK) by 29.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,450 shares of the company’s stock after purchasing an additional 1,000 shares during the quarter. Trust Co. of Oklahoma’s holdings in Merck & Co., Inc. were worth $405,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. BlackRock Inc. raised its position in shares of Merck & Co., Inc. by 2.3% during the second quarter. BlackRock Inc. now owns 191,863,408 shares of the company’s stock worth $16,087,745,000 after acquiring an additional 4,397,580 shares during the last quarter. Parametric Portfolio Associates LLC raised its position in shares of Merck & Co., Inc. by 1.5% during the third quarter. Parametric Portfolio Associates LLC now owns 11,408,929 shares of the company’s stock worth $960,404,000 after acquiring an additional 171,403 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its position in shares of Merck & Co., Inc. by 3.2% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,846,593 shares of the company’s stock worth $913,066,000 after acquiring an additional 338,355 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Merck & Co., Inc. by 0.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 10,253,759 shares of the company’s stock worth $863,162,000 after acquiring an additional 39,180 shares during the last quarter. Finally, California Public Employees Retirement System raised its position in shares of Merck & Co., Inc. by 11.9% during the third quarter. California Public Employees Retirement System now owns 10,174,164 shares of the company’s stock worth $856,461,000 after acquiring an additional 1,080,016 shares during the last quarter. Hedge funds and other institutional investors own 74.51% of the company’s stock.

In other Merck & Co., Inc. news, EVP Julie L. Gerberding sold 102,073 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $89.34, for a total value of $9,119,201.82. Following the completion of the transaction, the executive vice president now directly owns 106,099 shares of the company’s stock, valued at $9,478,884.66. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.27% of the stock is owned by insiders.

Shares of Merck & Co., Inc. stock opened at $85.98 on Friday. The company has a quick ratio of 0.98, a current ratio of 1.26 and a debt-to-equity ratio of 0.84. Merck & Co., Inc. has a 12 month low of $72.05 and a 12 month high of $92.64. The business has a fifty day simple moving average of $90.21 and a 200 day simple moving average of $85.77. The stock has a market cap of $225.47 billion, a PE ratio of 24.02, a price-to-earnings-growth ratio of 1.77 and a beta of 0.52.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $1.51 EPS for the quarter, topping analysts’ consensus estimates of $1.24 by $0.27. Merck & Co., Inc. had a return on equity of 48.16% and a net margin of 20.26%. The business had revenue of $12.40 billion during the quarter, compared to analysts’ expectations of $11.59 billion. During the same period in the previous year, the firm earned $1.19 earnings per share. The firm’s quarterly revenue was up 14.9% compared to the same quarter last year. Analysts expect that Merck & Co., Inc. will post 5.16 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 8th. Investors of record on Monday, December 16th were paid a dividend of $0.61 per share. The ex-dividend date of this dividend was Friday, December 13th. This is a boost from Merck & Co., Inc.’s previous quarterly dividend of $0.55. This represents a $2.44 dividend on an annualized basis and a dividend yield of 2.84%. Merck & Co., Inc.’s payout ratio is 56.22%.

MRK has been the subject of a number of recent research reports. Bank of America initiated coverage on Merck & Co., Inc. in a research report on Wednesday, October 16th. They set a “neutral” rating and a $90.00 target price for the company. Morgan Stanley boosted their target price on Merck & Co., Inc. from $90.00 to $95.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 13th. ValuEngine downgraded Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research report on Tuesday, January 14th. Royal Bank of Canada initiated coverage on Merck & Co., Inc. in a research report on Monday, January 6th. They set a “sector perform” rating and a $99.00 target price for the company. Finally, UBS Group boosted their target price on Merck & Co., Inc. from $94.00 to $99.00 and gave the stock a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $96.38.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: Correction

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.